New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml;   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - cefalexin - oral suspension - 25mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin -

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - cefalexin 125 mg/5ml - 125 mg/5ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - cefalexin 125 mg/5ml - 125 mg/5ml

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage);   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة دار الدواء للتنمية والأستثمار - dar al dawa development and investment co ltd - cefalexin 125 mg/5ml - 125 mg/5ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية جاوده الدولي - jaweda int. drud store - cefalexin 125 mg/5ml - 125 mg/5ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الشرق الاوسط للصناعات الدوائية - middle east pharmaceutical and chemical industries - cefalexin 125 mg/5ml - 125 mg/5ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الدولية للدواء - pharma international company - cefalexin 125 mg/5ml - 125 mg/5ml